Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics


Magenta Therapeutics, Inc. (MGTA): $7.79

0.92 (+13.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MGTA Stock Price Chart Interactive Chart >

Price chart for MGTA

MGTA Price/Volume Stats

Current price $7.79 52-week high $14.20
Prev. close $6.87 52-week low $5.89
Day low $6.94 Volume 1,085,100
Day high $7.86 Avg. volume 260,054
50-day MA $7.04 Dividend yield N/A
200-day MA $9.61 Market Cap 456.24M

Magenta Therapeutics, Inc. (MGTA) Company Bio


Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.


MGTA Latest News Stream


Event/Time News Detail
Loading, please wait...

MGTA Latest Social Stream


Loading social stream, please wait...

View Full MGTA Social Stream

Latest MGTA News From Around the Web

Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.

How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own?

A look at the shareholders of Magenta Therapeutics, Inc. ( NASDAQ:MGTA ) can tell us which group is most powerful...

Yahoo | August 9, 2021

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

CAMBRIDGE, Mass., August 05, 2021--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the second quarter ended June 30, 2021, and recent program highlights.

Yahoo | August 5, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Yahoo | August 3, 2021

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

CAMBRIDGE, Mass., August 03, 2021--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:

Yahoo | August 3, 2021

Were Hedge Funds Right About Magenta Therapeutics, Inc. (MGTA)?

No summary available.

Insider Monkey | July 30, 2021

Read More 'MGTA' Stories Here

MGTA Price Returns

1-mo 20.03%
3-mo -26.72%
6-mo -40.08%
1-year 0.91%
3-year -32.96%
5-year N/A
YTD -0.64%
2020 -48.28%
2019 165.96%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9584 seconds.